Pectus Respiratory Health S.L. — Clinical Trial Site

18 Registered trials

5 Currently recruiting

Organisation

Pectus Respiratory Health S.L.

Location

Barcelona, Spain

Identifier

ORG-100050545

Address

Josep Maria Gironella Str 11, 17005, Spain

Departments

Clinica Mi Tres Torres
Institut Català de Serveis Mèdics
Institut catala de Serveis Médics S.A
Neumology
Pectus Respiratoy Health S.L. (BCN)
Pneumologist
Pneumology
Pneumology and Respiratory Allergy
Pneumology Service
Research Facility

Clinical trials at this site (18)

Search interface

An Open-Label Extension to Study the Long-Term Effect of Dexpramipexole in Participants with Severe Eosinophilic Asthma (EXHALE-5) Under evaluation

2024-510810-33-00 Severe eosinophilic asthma 5 2024-10-14
A study to evaluate the efficacy, immunogenicity, and safety of an RSV and hMPV VLP vaccine compared with placebo in participants aged 60 ye… Pending

2024-513740-28-00 Respiratory Syncytial Virus and Human Metapneumovirus 5
BETRI-Prospective: Asthma control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 µg]) vs Single Inhaler ICS/LABA (200/… Pending

2025-524289-56-00 Asthma 6
Long-term safety and efficacy evaluation of lunsekimig (SAR443765) in adult participants with moderate-to-severe asthma. Recruiting

2025-522896-27-00 Asthma 4 2026-05-11
A study to investigate airway inflammation with dupilumab subcutaneously in participants aged ≥40 to ≤85 years with chronic obstructive pulm… Recruiting

2025-521268-37-00 Respiratory tract diseases 6 2025-11-25
Study of lunsekimig (SAR443765) compared with placebo in adults with high-risk asthma Recruiting

2024-513959-33-00 Asthma 4 2025-05-13
A dose finding study with an anti-TSLP antibody (GSK5784283) in adults aged 18 to 75 years of age with uncontrolled asthma. Ended

2024-518321-15-00 Asthma 4 2025-05-30
A Randomized, Double Blind, Active-Controlled Study on Efficacy and Safety of TEV-56248 in Patients with Asthma Ended

2023-505435-12-00 Asthma 5 2024-06-04
REIMAGINE – Real-world EvaluatIon of Mepolizumab in severe Asthma achievinG on treatment clinIcal remissioN, a prospEctive study. Ended

2023-509026-21-00 severe asthma 6 2024-06-03
A Phase 3, 52-Week, Randomized, Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory or Une… Ended

2024-513460-26-00 Refractory Chronic Cough, Including Unexplained Chronic 5 2023-03-29
A Phase 1/2a Study Evaluating the Effects of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosi… Ended

2023-504964-41-00 Idiopathic pulmonary fibrosis 7 2024-11-06
Phase 2 study to evaluate the efficacy and safety of GSK3915393 in participants with Idiopathic Pulmonary Fibrosis (IPF) Ended

2023-509371-16-00 Idiopathic Pulmonary Fibrosis 4 2024-09-25
A study to assess and compare safety and tolerability of 3 months treatment with salbutamol administered via MDI containing propellant HFA-1… Ended

2023-509001-76-00 Asthma 5 2024-07-01
A Proof-of-Concept study to assess the efficacy, safety and tolerability of itepekimab (anti-IL-33 mAb) in participants with non-cystic fibr… Ended

2023-508663-70-00 Bronchiectasis 4 2024-06-18
A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Ended

2023-503693-20-01 Severe eosinophilic asthma 5 2024-04-10
Study Evaluating the Effects of ARO-RAGE in Healthy Subjects and Patients with Inflammatory Lung Disease Ended

2023-509654-60-00 Inflammatory Lung Disease 9 2023-06-21
A Phase 1/2a Study Evaluating the Effects of ARO-MUC5AC Inhalation Solution in Healthy Subjects and Patients with Muco-Obstructive Lung Dise… Ended

2024-514809-67-00 Asthma and Chronic obstructive pulmonary disease 9 2023-06-21
Non-inferiority study of GSK3511294 (depemokimab) compared with mepolizumab or benralizumab in participants with severe asthma with an eosin… Ended

2023-510230-84-00 Severe asthma with an eosinophilic phenotype 5 2021-05-28